Clarity Pharmaceuticals Surpasses 220-Patient Target in Phase III Imaging Trial

Trial Milestone Achieved

Clarity Pharmaceuticals, an Australian clinical-stage biotech, has announced that its Phase III AMPLIFY trial has successfully enrolled more participants than initially planned. The trial, which began in May 2025, aims to evaluate Cu-SAR-bisPSMA, a novel diagnostic imaging agent designed to detect biochemical recurrence of prostate cancer. Recruitment was completed across multiple sites in the United States and Australia, reflecting strong demand from both clinicians and patients.

Advancing Prostate Cancer Diagnostics

The AMPLIFY trial assesses Cu-SAR-bisPSMA’s ability to identify recurrent prostate cancer through PET/CT imaging at two timepoints post-administration. This agent leverages Clarity’s proprietary sarcophagine technology to securely bind copper isotopes, offering potential advantages over existing PSMA PET imaging agents. Early-phase studies, including the COBRA and Co-PSMA trials, have demonstrated that Cu-SAR-bisPSMA can detect lesions at rates two to three times higher than current standard-of-care products.

Strategic Clinical Development

Alongside AMPLIFY, Clarity is conducting the CLARIFY trial, another Phase III study focusing on pelvic lymph node detection in prostate cancer patients scheduled for surgery. Both trials aim to build a comprehensive data package to support regulatory submissions to the US Food and Drug Administration. The company has also secured three Fast Track Designations for SAR-bisPSMA, underscoring the FDA’s recognition of its potential clinical impact.

Market and Patient Implications

Prostate cancer remains a leading cause of cancer-related death among men globally, with over 330,000 new cases expected in the US alone in 2026. Clarity’s imaging agent addresses a critical unmet need for more accurate and timely detection of disease recurrence, which can guide treatment decisions and improve patient outcomes. The rapid enrolment pace despite existing commercial products highlights the strong clinical interest in Cu-SAR-bisPSMA.

Looking Ahead

With enrolment complete, Clarity will focus on finalising data analysis and engaging with regulatory authorities to expedite approval. The company also anticipates closing recruitment in the CLARIFY trial later this year and advancing its theranostic SECuRE trial. These milestones collectively bring Clarity closer to commercialising a next-generation diagnostic tool that could reshape prostate cancer management.